Akt-dependent regulation of NF-κB is controlled by mTOR and Raptor in association with IKK

Genes and Development

Volumn 22, Issue 11, 2008, Pages 1490-1500

  Dan, Han C ^a   Cooper, Matthew J ^a   Cogswell, Patricia C ^a   Duncan, Joseph A ^a   Ting, Jenny P Y ^a   Baldwin, Albert S ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Akt; IKK; mTOR; NF B; Raptor

Indexed keywords

I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN; PROTEIN KINASE B; RAPAMYCIN; RAPTOR PROTEIN;

ARTICLE; CANCER CELL; CONTROLLED STUDY; DISSOCIATION; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; NULL ALLELE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

GENE EXPRESSION REGULATION; HELA CELLS; HUMANS; I-KAPPA B KINASE; MALE; NF-KAPPA B; PROSTATIC NEOPLASMS; PROTEIN KINASES; PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SIROLIMUS; TUMOR CELLS, CULTURED;

MAMMALIA; RAPTORES;

EID: 44849117768     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.1662308     Document Type: Article

References (48)

1. Agarwal, A., Das, K., Lerner, N., Sathe, S., Cicek, M., Casey, G., and Sizemore, N. 2005. The Akt/IKK pathway promotes angiogenic/metastatic gene expression in colorectal cancer by activating NF-κB and β-catenin. Oncogene 24: 1021-1031.
2. Basseres, D. and Baldwin, A. 2006. NF-κB and IKK pathways in oncogenic initiation and progression. Oncogene 25: 6817-6830.
3. Bhaskar, P.T. and Hay, N. 2007. The two TORCs and Akt. Dev. Cell 12: 487-502.
4. Bonizzi, G. and Karin, M. 2004. The two NF-κB activation pathways and their roles in innate and adaptive immunity. Trends Immunol. 25: 280-288.
5. Cantley, L.C. and Neel, B.G. 1999. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the PI3K/Akt pathway. Proc. Natl. Acad. Sci. 96: 4240-4245.
6. Chen, G., Cao, P., and Goeddel, D.V. 2002. TNF-induced recruitment and activation of the IKK complex require Cdc37 and Hsp90. Mol. Cell 9: 401-410.
7. +/- mice. Genes & Dev. 20: 1569-1574.
8. Dan, H., Adli, M., and Baldwin, A.S. 2007. Regulation of mammalian target of rapamycin activity in PTEN-inactive prostate cancers by IKKα. Cancer Res. 67: 6263-6269.
9. Delhase, M., Li, N., and Karin, M. 2000. Signaling pathways: Kinase regulation in inflammatory response. Nature 406: 367-368.
10. Downward, J. 1998. Mechanisms and consequences of activation of protein kinase B/Akt. Curr. Opin. Cell Biol. 10: 262-267.
11. Fingar, D.C. and Blenis, J. 2004. Target of rapamycin (TOR): An integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23: 3151-3171.
12. Ghosh, S., Tergaonkar, V., Rothlin, C., Correa, R., Bottero, V., Bist, P., Verma, I., and Hunter, T. 2006. Essential role of tuberous sclerosis genes TSC1 and TSC2 in NF-kB activation and survival. Cancer Cell 10: 215-226.
13. Guertin, D.A. and Sabatini, D.M. 2005. An expanding role for mTOR in cancer. Trends Mol. Med. 8: 353-361.
14. Hahn-Windgassen, A., Nogueira, V., Chen, C.C., Skeen, J.E., Sonenberg, N., and Hay, N. 2005. Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J. Biol. Chem. 280: 32081-32089.
15. Hara, K., Maruki, Y., Long, X., Yoshino, K., Oshiro, N., Hidayat, S., Tokunaga, C., Avruch, J., and Yonezawa, K. 2002. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110: 177-189.
16. Hay, N. 2005. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 8: 179-183.
17. Hay, N. and Sonenberg, N. 2004. Upstream and downstream of mTOR. Genes & Dev. 18: 1926-1945.
18. Hayden, M. and Ghosh, S. 2004. Signaling to NF-κB. Genes & Dev. 18: 2195-2224.
19. Inoki, K., Li, Y., Zhu, T., Wu, J., and Guan, K.L. 2003. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signaling. Nat. Cell Biol. 4: 648-657.
20. Israel, A. 2000. The IKK complex: An integrator of all signals that activate NF-κB? Trends Cell Biol. 10: 129-133.
21. Karin, M. 2006. NF-κB in cancer development and progression. Nature 441: 431-436.
22. Kim, D.H., Sarbassov, D., Ali, S., King, J., Latek, R., Erdjument-Bromage, H., Tempst, P., and Sabatini, D.M. 2002. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110: 163-175.
23. Kim, D.H., Sarbassov, D., Ali, S.M., Latek, R., Guntur, K., Erdjument-Bromage, H., Tempst, P., and Sabatini, D.M. 2003. GβL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol. Cell 11: 895-904.
24. Lee, D., Kuo, H., Chen, C., Hsu, J., Chou, C., Wei, Y., Sun, H., Li, L., Ping, B., Huang, W., et al. 2007. IKKβ suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 130: 440-455.
25. Madrid, L., Mayo, M., Reuther, J., and Baldwin, A.S. 2001. Akt stimulates the transactivation potential of the RelA/p65 subunit of NF-κB through utilization of IKK and activation of mitogen activated protein kinase p38. J. Biol. Chem. 276: 18934-18940.
26. Majumder, P.K. and Sellers, W.R. 2005. Akt-regulated pathways in prostate cancer. Oncogene 24: 7465-7474.
27. Majumder, P., Febbo, P., Bikoff, R., Berger, R., Xue, Q., McMahon, L., Manola, J., Brugarolas, J., McDonnell, T., Golub, T., et al. 2004. MTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat. Med. 10: 594-601.
28. Manning, B.D. and Cantley, L.C. 2003. Rheb fills a GAP between TSC and TOR. Trends Biochem. Sci. 28: 573-576.
29. Manning, B.D. and Cantley, L.C. 2007. Akt/PKB signaling: Navigating downstream. Cell 129: 1261-1274.
30. Mayo, M., Wang, C.Y., Cogswell, P., Rogers-Graham, K., Lowe, S., Der, C., and Baldwin, A.S. 1997. Requirement of NF-κB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science 278: 1812-1815.
31. Neshat, M., Melinghoff, I., Tran, C., Stiles, B., Thomas, G., Petersen, R., Frost, P., Gibbons, J., Wu, H., and Sawyers, C.L. 2001. Enhanced sensitivity to PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. 98: 10314-10319.
32. O'Reilly, A., Rojo, F., She, Q., Solit, D., Mills, G., Smith, D., Lane, H., Hofmann, F., Hicklin, D., Ludwig, D., et al. 2006. mTOR inhibition induces upstream tyrosine kinase signaling and activates Akt. Cancer Res. 66: 1500-1508.
33. Ozes, O., Mayo, L.D., Gustin, J.A., Pfeffer, S., Pfeffer, L., and Donner, D. 1999. NF-κB activation by TNF requires the Akt serine-threonine kinase. Nature 401: 82-85.
34. Plas, D.R. and Thompson, C.B. 2005. Akt-dependent transformation: There is more to growth than just survival. Oncogene 24: 7435-7442.
35. +/- mice. Proc. Natl. Acad. Sci. 98: 10320-10325.
36. Sabatini, D.M. 2006. mTOR and cancer: Insights into a complex relationship. Nat. Rev. Cancer 6: 729-734.
37. Sarbassov, D., Guertin, D., Ali, S.M., and Sabatini, D.M. 2005. Phosphorylation and regulation of Akt/PKB by the Rictor-mTOR complex. Science 307: 1098-1101.
38. Sarbassov, D., Ali, S., Sengupta, S., Sheen, J., Hsu, P., Bagley, A., Markhard, A., and Sabatini, D.M. 2006. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22: 159-168.
39. Sawyers, C.L. 2003. Will mTOR inhibitors make it as cancer drugs? Cancer Cell 4: 343-348.
40. Shah, O.J. and Hunter, T. 2006. Turnover of the active fraction of IRS1 involves raptor-mTOR and S6K1-dependent serine phosphorylation in cell culture models of tuberous sclerosis. Mol. Cell. Biol. 26: 6425-6434.
41. Shaw, R.J. and Cantley, L.C. 2006. Ras, PI(3)K, and mTOR signaling controls tumor cell growth. Nature 441: 424-430.
42. Sizemore, N., Lerner, N., Dombrowski, N., Sakurai, H., and Stark, G. 2002. Distinct roles of IKKα and IKKβ in liberating NF-κB from IκB and in phosphorylating the p65 subunit of NF-κB. J. Biol. Chem. 277: 3863-3869.
43. Skeen, J., Bhaskar, P., Chen, C.-C., Chen, W.S., Peng, X.-D., Nogueira, V., Hahn-Windgassen, A., Kiyokawa, H., and Hay, N. 2006. Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-dependent and mTORC1-dependent manner. Cancer Cell 10: 269-280.
44. Steinbrecher, K., Wilson, W., Cogswell, P., and Baldwin, A.S. 2005. GSK3β functions to specify gene specific, NF-kB-dependent transcription. Mol. Cell. Biol. 25: 8444-8455.
45. Thomas, G., Tran, C., Mellinghoff, I., Welsbie, D., Chan, E., Fueger, B., Czemin, J., and Sawyers, C.L. 2006. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat. Med. 12: 122-127.
46. Tran, H., Brunet, A., Griffith, E., and Greenberg, M.E. 2003. The many forks in FOXO's road. Sci. STKE 2003: RE5. doi: 10.1126/stke.2003.172.re5.
47. Vivanco, I. and Sawyers, C.L. 2002. The phosphatidylinositol 3-kinase pathway and human cancer. Nat. Rev. Cancer 2: 489-501.
48. Yang, Q., Inoki, K., Ikenoue, T., and Guan, K.L. 2006. Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes & Dev. 20: 2820-2832.